AU2016270973B2 - Tyrosine kinase inhibitors - Google Patents

Tyrosine kinase inhibitors Download PDF

Info

Publication number
AU2016270973B2
AU2016270973B2 AU2016270973A AU2016270973A AU2016270973B2 AU 2016270973 B2 AU2016270973 B2 AU 2016270973B2 AU 2016270973 A AU2016270973 A AU 2016270973A AU 2016270973 A AU2016270973 A AU 2016270973A AU 2016270973 B2 AU2016270973 B2 AU 2016270973B2
Authority
AU
Australia
Prior art keywords
compound
disease
amino
pharmaceutically acceptable
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016270973A
Other languages
English (en)
Other versions
AU2016270973A1 (en
Inventor
David Goldstein
Timothy D. Owens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Principia Biopharma Inc
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of AU2016270973A1 publication Critical patent/AU2016270973A1/en
Application granted granted Critical
Publication of AU2016270973B2 publication Critical patent/AU2016270973B2/en
Priority to AU2020203447A priority Critical patent/AU2020203447B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Diabetes (AREA)
AU2016270973A 2015-06-03 2016-06-02 Tyrosine kinase inhibitors Active AU2016270973B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203447A AU2020203447B2 (en) 2015-06-03 2020-05-26 Tyrosine kinase inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562170547P 2015-06-03 2015-06-03
US62/170,547 2015-06-03
US201562271689P 2015-12-28 2015-12-28
US62/271,689 2015-12-28
PCT/US2016/035588 WO2016196840A1 (en) 2015-06-03 2016-06-02 Tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203447A Division AU2020203447B2 (en) 2015-06-03 2020-05-26 Tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2016270973A1 AU2016270973A1 (en) 2018-01-18
AU2016270973B2 true AU2016270973B2 (en) 2020-05-14

Family

ID=56118090

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016270973A Active AU2016270973B2 (en) 2015-06-03 2016-06-02 Tyrosine kinase inhibitors
AU2020203447A Active AU2020203447B2 (en) 2015-06-03 2020-05-26 Tyrosine kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203447A Active AU2020203447B2 (en) 2015-06-03 2020-05-26 Tyrosine kinase inhibitors

Country Status (33)

Country Link
US (5) US20180162861A1 (OSRAM)
EP (3) EP4112618A1 (OSRAM)
JP (2) JP6646072B2 (OSRAM)
KR (3) KR102666352B1 (OSRAM)
CN (2) CN113149983B (OSRAM)
AU (2) AU2016270973B2 (OSRAM)
CA (1) CA2987335A1 (OSRAM)
CL (2) CL2017003073A1 (OSRAM)
CO (1) CO2017012947A2 (OSRAM)
CR (1) CR20170593A (OSRAM)
DK (1) DK3303334T3 (OSRAM)
DO (1) DOP2017000279A (OSRAM)
EA (1) EA039006B1 (OSRAM)
ES (1) ES2878030T3 (OSRAM)
HK (1) HK1252378A1 (OSRAM)
HR (1) HRP20211249T1 (OSRAM)
HU (1) HUE055419T2 (OSRAM)
IL (2) IL255946A (OSRAM)
LT (1) LT3303334T (OSRAM)
MX (2) MX395007B (OSRAM)
MY (1) MY190548A (OSRAM)
PE (1) PE20180521A1 (OSRAM)
PH (2) PH12017502203B1 (OSRAM)
PL (1) PL3303334T3 (OSRAM)
PT (1) PT3303334T (OSRAM)
RS (1) RS62290B1 (OSRAM)
SG (1) SG10201912443XA (OSRAM)
SI (1) SI3303334T1 (OSRAM)
TN (1) TN2017000501A1 (OSRAM)
TW (2) TWI732765B (OSRAM)
UA (1) UA124090C2 (OSRAM)
WO (1) WO2016196840A1 (OSRAM)
ZA (2) ZA201708667B (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150044271A1 (en) 2012-02-27 2015-02-12 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
RS58956B1 (sr) 2012-09-10 2019-08-30 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
CN105764814B (zh) 2013-11-29 2019-02-19 株式会社大造 内容物收容容器、使用其的内容物收容制品、排出制品及排出装置
EA033900B1 (ru) 2014-02-21 2019-12-06 Принсипиа Биофарма Инк. СОЛЕВЫЕ И АМОРФНЫЕ ФОРМЫ 2-[(3R)-3-[4-АМИНО-3-(2-ФТОР-4-ФЕНОКСИФЕНИЛ)ПИРАЗОЛО[3,4-d]ПИРИМИДИН-1-ИЛ]ПИПЕРИДИН-1-КАРБОНИЛ]-4-МЕТИЛ-4-[4-(ОКСЕТАН-3-ИЛ)ПИПЕРАЗИН-1-ИЛ]ПЕНТ-2-ЕННИТРИЛА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ПУЗЫРЧАТКИ ОБЫКНОВЕННОЙ И ПУЗЫРЧАТКИ ЛИСТОВИДНОЙ С ИХ ПРИМЕНЕНИЕМ
CA2970723C (en) 2014-12-18 2023-09-05 Principia Biopharma Inc. Treatment of pemphigus
KR102666352B1 (ko) * 2015-06-03 2024-05-17 프린시피아 바이오파마, 인코퍼레이티드 티로신 키나제 억제제
EP3313839A1 (en) 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
CA3008653A1 (en) * 2015-10-14 2017-04-20 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
SG11201811255WA (en) 2016-06-29 2019-01-30 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
JP6920411B2 (ja) * 2016-07-25 2021-08-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのプリン及び３−デアザプリンアナログ
WO2018156901A1 (en) * 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
EP3789040A4 (en) * 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
CA3224945C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR102830577B1 (ko) * 2018-09-13 2025-07-08 깃세이 야쿠힌 고교 가부시키가이샤 이미다조피리디논 화합물
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
CN115209899A (zh) 2019-10-14 2022-10-18 普林斯匹亚生物制药公司 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法
TWI883107B (zh) 2020-01-20 2025-05-11 美商普林斯匹亞生物製藥公司 用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑
MX2022009009A (es) 2020-01-22 2022-08-15 Principia Biopharma Inc Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115397427A (zh) * 2020-03-30 2022-11-25 Igia制药有限公司 酪氨酸激酶抑制剂的儿科制剂
CN115701997B (zh) * 2020-08-10 2024-09-13 江苏恒瑞医药股份有限公司 Btk抑制剂治疗疾病的用途
KR20230051227A (ko) 2020-08-14 2023-04-17 노파르티스 아게 헤테로아릴 치환된 스피로피페리디닐 유도체 및 이의 제약 용도
CN116507627A (zh) 2020-11-02 2023-07-28 勃林格殷格翰国际有限公司 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物
WO2022121670A1 (zh) 2020-12-10 2022-06-16 苏州科睿思制药有限公司 Tolebrutinib的晶型及其制备方法和用途
CN116710452A (zh) * 2020-12-23 2023-09-05 建新公司 4-氨基-3-(4-苯氧基苯基)-1,3-二氢-2h-咪唑并[4,5-c]吡啶-2-酮衍生物及其盐类
AU2021409575A1 (en) * 2020-12-23 2023-08-10 Principia Biopharma Inc. 4-amino-3-(4-phenoxyphenyl)-1,3- dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2022218430A1 (zh) * 2021-04-16 2022-10-20 南京明德新药研发有限公司 咪唑并吡啶类化合物及其应用
CN117295735A (zh) 2021-04-23 2023-12-26 杭州领业医药科技有限公司 Tolebrutinib晶型、无定型及其制备方法和用途
CN117412749A (zh) * 2021-05-21 2024-01-16 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
IL309263A (en) 2021-06-11 2024-02-01 Genzyme Corp Crystalline form of tolbrotinib, method of preparation and use thereof
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
EP4404937A4 (en) * 2021-09-24 2025-10-15 Chadwick Donaldson DRY POWDER FOAMING FORMULATIONS FOR DRUG DELIVERY ACROSS THE MUCOSA
CA3241687A1 (en) 2021-12-21 2023-06-29 Tim Owens Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof
EP4490156A1 (en) * 2022-03-09 2025-01-15 Teva Pharmaceuticals International GmbH Solid state forms of tolebrutinib and of tolebrutinib salts
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
IL317645A (en) * 2022-06-14 2025-02-01 Principia Biopharma Inc Methods for preparing tolbrutinib
KR20250025711A (ko) * 2022-06-22 2025-02-24 프린시피아 바이오파마, 인코퍼레이티드 변형된 btk 저해제의 제조 방법
WO2024006406A1 (en) 2022-06-30 2024-01-04 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
AU2023361384A1 (en) 2022-10-11 2025-05-22 Principia Biopharma Inc. Therapeutic tyrosine kinase inhibitors for multiple sclerosis
CN118891260B (zh) * 2022-11-07 2025-07-25 天津瑞程健达医药科技有限公司 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物
TW202432128A (zh) 2022-12-20 2024-08-16 美商健臻公司 （Ｒ）－１－（１－丙烯醯基哌啶－３－基）－４－胺基－３－（４－苯氧基苯基）－１Ｈ－咪唑並［４，５－ｃ］吡啶－２（３Ｈ）－酮之藥品調配物
IL322398A (en) 2023-02-01 2025-09-01 Principia Biopharma Inc Methods for diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid and spinal cord
US20250282777A1 (en) 2024-03-06 2025-09-11 Principia Biopharma Inc. Methods of Making Tolebrutinib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086634A2 (en) * 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2012158764A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP2578585A1 (en) * 2010-05-31 2013-04-10 ONO Pharmaceutical Co., Ltd. Purinone derivative

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
AU2005284835A1 (en) * 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
AU2007257423B8 (en) 2006-05-31 2012-02-16 The Regents Of The University Of California Purine analogs
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
NZ598705A (en) 2009-09-16 2014-06-27 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
BR112013029508B1 (pt) * 2011-05-17 2022-05-03 Principia Biopharma, Inc. Composto, composição farmacêutica, e, uso do referido composto
WO2012158785A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
DK2786996T3 (en) * 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
MX368112B (es) * 2012-06-18 2019-09-18 Principia Biopharma Inc Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias.
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
RS58956B1 (sr) * 2012-09-10 2019-08-30 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
US20140142099A1 (en) * 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
KR102666352B1 (ko) * 2015-06-03 2024-05-17 프린시피아 바이오파마, 인코퍼레이티드 티로신 키나제 억제제
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
CA3008653A1 (en) 2015-10-14 2017-04-20 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086634A2 (en) * 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP2578585A1 (en) * 2010-05-31 2013-04-10 ONO Pharmaceutical Co., Ltd. Purinone derivative
WO2012158764A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
CA2987335A1 (en) 2016-12-08
AU2016270973A1 (en) 2018-01-18
PH12017502203A1 (en) 2018-06-11
JP6985433B2 (ja) 2021-12-22
IL255946A (en) 2018-01-31
MX395007B (es) 2025-03-24
JP2020073561A (ja) 2020-05-14
IL279258A (en) 2021-01-31
ZA202401324B (en) 2025-05-28
US20170129890A1 (en) 2017-05-11
DOP2017000279A (es) 2018-04-15
KR20220146657A (ko) 2022-11-01
US20210171526A1 (en) 2021-06-10
AU2020203447B2 (en) 2021-04-01
US20180162861A1 (en) 2018-06-14
KR20240070721A (ko) 2024-05-21
SI3303334T1 (sl) 2021-09-30
TWI732765B (zh) 2021-07-11
KR20180021730A (ko) 2018-03-05
CN106459049B (zh) 2020-11-27
CN113149983B (zh) 2024-03-29
AU2020203447A1 (en) 2020-06-11
ES2878030T3 (es) 2021-11-18
JP6646072B2 (ja) 2020-02-14
RS62290B1 (sr) 2021-09-30
SG10201912443XA (en) 2020-02-27
US9688676B2 (en) 2017-06-27
HUE055419T2 (hu) 2021-11-29
US20250197402A1 (en) 2025-06-19
TN2017000501A1 (en) 2019-04-12
NZ776815A (en) 2024-10-25
IL279258B (en) 2022-04-01
CL2017003073A1 (es) 2018-06-08
BR112017025850A2 (pt) 2018-08-14
UA124090C2 (uk) 2021-07-21
EP3912979A1 (en) 2021-11-24
JP2018516935A (ja) 2018-06-28
TWI810582B (zh) 2023-08-01
MX2021006571A (es) 2022-08-25
NZ738458A (en) 2024-10-25
MX383213B (es) 2025-03-13
CR20170593A (es) 2018-05-14
KR102552653B1 (ko) 2023-07-07
PE20180521A1 (es) 2018-03-14
PH12021551681A1 (en) 2023-08-23
PL3303334T3 (pl) 2021-11-08
CL2019002150A1 (es) 2019-11-29
CO2017012947A2 (es) 2018-03-28
HK1252378A1 (zh) 2019-05-24
EA039006B1 (ru) 2021-11-19
KR102666352B1 (ko) 2024-05-17
TW201713654A (zh) 2017-04-16
ZA201708667B (en) 2024-07-31
EA201792529A1 (ru) 2018-05-31
MX2017015470A (es) 2018-08-15
MY190548A (en) 2022-04-27
CN113149983A (zh) 2021-07-23
WO2016196840A1 (en) 2016-12-08
EP3303334A1 (en) 2018-04-11
DK3303334T3 (da) 2021-06-28
PH12017502203B1 (en) 2022-07-22
CN106459049A (zh) 2017-02-22
TW202210478A (zh) 2022-03-16
EP4112618A1 (en) 2023-01-04
LT3303334T (lt) 2021-07-12
EP3303334B1 (en) 2021-06-02
HRP20211249T1 (hr) 2021-11-12
US20230151012A1 (en) 2023-05-18
PT3303334T (pt) 2021-07-02

Similar Documents

Publication Publication Date Title
AU2020203447B2 (en) Tyrosine kinase inhibitors
US11155544B2 (en) Heterocycle comprising tyrosine kinase inhibitors
US20210015821A1 (en) Salts and solid form of a btk inhibitor
EP2861599B1 (en) Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment of cancer and autoimmune diseases
HK40086068A (en) Tyrosine kinase inhibitors
HK40050010A (en) Tyrosine kinase inhibitors
HK40050010B (zh) 酪氨酸激酶抑制剂
BR112017025850B1 (pt) Compostos inibidores de tirosina quinase, seus usos e composição farmacêutica
BR122021003286B1 (pt) Compostos inibidores de tirosina quinase, seus usos e composição farmacêutica
HK1234403A1 (en) Tyrosine kinase inhibitors
HK1234403B (zh) 酪氨酸激酶抑制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)